Description: SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Home Page: www.sillajen.com
109, Sogong-ro
Seoul,
04525
South Korea
Phone:
82 2 368 2600
Officers
| Name | Title |
|---|---|
| Mr. Jaekyung Kim | CEO & Chairman of the Board |
| Suk Song Myung | Chief Financial Officer |
| Mr. Eun-Ki Min | Chief Accounting Officer and Executive Director |
| Chan Kwon Hyuk M.D., Ph.D. | Chief Medical Officer |
| Mee Yang Kyung Ph.D. | Head of R&D Strategic Planning |
| Mr. Jaejeong Lee | Executive Officer |
| Mr. Jeongseok Lee | Executive Officer |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9237 |
| Price-to-Sales TTM: | 229.4762 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 37 |